

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 31/78</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/14833</b> <b>(43) International Publication Date:</b> 13 December 1990 (13.12.90)
<b>(21) International Application Number:</b> PCT/US90/03219 <b>(22) International Filing Date:</b> 7 June 1990 (07.06.90)  <b>(30) Priority data:</b> 362,529 7 June 1989 (07.06.89) US 429,051 30 October 1989 (30.10.89) US  <b>(60) Parent Applications or Grants</b> <b>(63) Related by Continuation</b> US 362,529 (CIP) Filed on 7 June 1989 (07.06.89) US 429,051 (CIP) Filed on 30 October 1989 (30.10.89)  <b>(71)(72) Applicant and Inventor:</b> BAZZANO, Gail, S. [US/US]; 4506 Avron Boulevard, Metairie, LA 70006 (US).			<b>(74) Agents:</b> SCHWARZE, William, W. et al.; Panitch Schwarze Jacobs & Nadel, 1601 Market Street, 36th Floor, Philadelphia, PA 19103 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European pa- tent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (Euro- pean patent), JP, LU (European patent), NL (European patent), SE (European patent), US .  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS			
<b>(57) Abstract</b>  Stable, aqueous gel vehicles are provided for the topical application to the skin of irritating active ingredients such as reti- noids, particularly tretinoin, with slow release of the active ingredient and minimal irritancy to the skin. The vehicles include a gelling agent effective to form a gel and hold the active ingredient in the aqueous medium for slow release on the skin, and an effective amount of an antioxidant to retard decomposition of the active ingredient. The vehicles and formulations are preferably aqueous emulsions which contain a solubilizing agent for the generally non-water soluble active ingredients, as well as usually an emulsifying agent and/or surfactant. Chelating agents, emollients, preservatives and other adjuvants and additives may also be included in the vehicles and formulations.			

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

-1-

SLOW RELEASE VEHICLES FOR MINIMIZING  
SKIN IRRITANCY OF TOPICAL COMPOSITIONS

Field of the Invention

5           The invention relates to stabilized,  
slow-release vehicles for normally irritating,  
non-water soluble active ingredients for topical  
application to the skin. More particularly, the  
invention is directed to aqueous emulsion  
10 formulations of retinoids for topical application  
to individuals who are sensitive to retinoids in  
other vehicles.

Background of the Invention

Topical retinoids have been widely used  
15 for multiple cutaneous disorders, as reported in A.  
Haas et al. "Selected Therapeutic Applications of  
Topical Tretinoin," JAAD, 15:870 (1986) (See Table  
I below). In many instances, the application of  
tretinoin has alleviated or induced remission in  
20 many such conditions, although these disorders  
reflect a variety of pathogenic mechanisms.

-2-

Table I  
Selected Therapeutic Application  
of Topical Tretinoin

	Disorders with altered keratinization
5	Acneiform follicular, or nevroid
	Nevus comedeonicus
	Senile comedones
	Steroid folliculitis
	Pseudofolliculitis
10	Fox-Fordyce disease
	Hair casts
	Monilethrix
	Alopecia
	Trichrostasis spinulosa
15	Linear verrucous nevus
	Ichthyosiform
	Epidermolytic hyperkeratosis
	(congenital ichthyosiform
	erythroderma)
20	Ichthyosis vulgaris
	Lamellar ichthyosis
	X-linked ichthyosis
	Psoriasiform, hyperkeratotic, or
	dyskeratotic
25	Acanthosis and pseudoacanthosis
	nigricans
	Callosities
	Keratosis follicularis (Darier's)
	Keratosis palmaris et plantaris
30	Kyrle's disease
	Psoriasis
	Reactive perforating collagenosis

-3-

- Infectious/inflammatory disorders
  - Molluscum contagiosum
  - Flat warts
  - Plantar warts
  - 5 Tinea versicolor
  - Leg ulcers
  - Keloids and hypertrophic scars
  - Mucocutaneous disorders
  - Geographic tongue
  - 10 Lichen planus
  - Leukoplakia
  - Xerophthalmia (dry eye)
  - Hairy leukoplakia
  - Pigmentation disorders
  - 15 Ephelides
  - Melasma
  - Postinflammatory hyperpigmentation
  - Malignant and premalignant disorders
  - Actinic keratoses, photoaging
  - 20 Keratoacanthomas
  - Melanomas
  - Certival dysplasia
  - Basal cell epithelioma
- 25 It has been demonstrated that prolonged topical application of Vitamin A acid (tretinoin or all-trans retinoic acid) is effective in the treatment of acne (See U.S. Patent 3,729,568 and Kligman, A.M., "Topical Vitamin A Acid in Acne Vulgaris," Arch. Derm., 99:469-476 (1969)).
- 30 Kligman utilizes a composition in which Vitamin A acid is dispersed in a water miscible (substantially oil- and fat-free) liquid carrier

-4-

having high solvating action. The topical application of this Vitamin A acid composition causes irritation of the skin in the treated areas. A presently available gel form with alcohol base or  
5 cream formulation also causes irritation. (See U.S. Patents 3,906,108 and 4,247,547.)

A cream formulation of tretinoin is presently approved and is commercially available from Ortho Pharmaceutical Company under the  
10 trademark RETIN-A. It contains a therapeutically effective amount of tretinoin, a hydrophobic material selected from the liquid and solid fatty acids, fatty alcohols, fatty acid esters, pharmaceutical grades of waxes and hydrocarbons,  
15 the latter ranging from liquids through semisolids, such as petrolatum, to solids, and the like, a non-ionic emulsifier, xanthan gum, a preservative, an antioxidant and water. This formulation is more generally acceptable in a low dose 0.025%  
20 formulation, but it is still unacceptable to certain individuals with sensitive skin for continued daily applications.

Furthermore, the above tretinoin cream is relatively dense and pasty, and the pharmaceutical  
25 base is not elegant. The necessity to stabilize the cream with xanthan gum and to apply daily or twice daily a fatty substrate to the skin leaves a greasy film with a pasty residue.

Therefore, the problem has been to find  
30 vehicles for retinoids, particularly tretinoin, and other irritating active ingredients in which the active ingredient would remain stable and non-

-5-

oxidized in the presence of large amounts of water, while dramatically reducing the amount of irritation caused by the active ingredient. It is also desirable to have a vehicle which can provide  
5 sufficient hydration to allow good percutaneous absorption, while at the same time allowing the active ingredient to be spread very thinly over the skin.

#### Brief Summary of the Invention

10 According to the present invention, stable, aqueous retinoid formulations are provided for topical application to the skin, with slow release and stability of the retinoid and minimal irritancy to the skin. The formulations comprise  
15 an aqueous medium, an amount of retinoid effective for treatment of a skin condition, a gelling agent in an amount effective to form a gel and hold the retinoid in the aqueous medium for slow release, and an antioxidant to retard decomposition of the  
20 retinoid in the aqueous medium. The formulations are particularly adapted for use with tretinoin and dermatologically acceptable salts, isomers and derivatives thereof, and the gelling agent is preferably a high molecular weight polyacrylic acid  
25 which is neutralized to a pH of about 3 to 7.

In addition to the above ingredients, the formulations of the invention preferably also include a solubilizing agent for the retinoid, a non-ionic emulsifying agent to form a stable  
30 emulsion of the retinoid in the aqueous medium, a lipophilic agent which may serve as an emollient, and a chelating agent to assist in holding the

-6-

retinoid for slow release. Surfactants, preservatives and other suitable additives may also be included. Moreover, the aqueous emulsion vehicles according to the present invention may  
5 also be used for the topical application of other normally irritating, non-water soluble active ingredients besides retinoids.

Detailed Description of  
the Preferred Embodiments

10 According to the present invention, it has been found that vehicles described herein can be used very effectively in order to prevent and retard the amount of irritation caused by topically applied retinoids. These vehicles allow good  
15 percutaneous absorption and at the same time provide a very high degree of hydration without causing oxidation of the retinoid molecule. The use of a slow-release vehicle based on a polyacrylate gelling agent in an aqueous medium is  
20 surprising because it has been thought previously that gels containing a high degree of water would cause great instability in the retinoid molecule. Also, it was thought that a gel formulation containing water as a primary base would lead to  
25 residues of retinoid aggregating on the skin without allowing percutaneous absorption, thereby leading to an inactive retinoid product which would readily oxidize on the skin.

I have discovered that surprisingly the  
30 gelling agent actually acts as a compound which allows stabilization of the retinoid and slowly



-7-

releases it so that it can optimally feed into the keratinocyte layers and dermal cells of the skin.

The vehicles and formulations of the present invention are particularly useful to  
5 patients who are sensitive to irritating active ingredients, particularly retinoids such as tretinoin. Thus, the slow-release vehicle provides a great improvement in skin comfort and ease of application and reduces the side effects normally  
10 associated with topical application of such active ingredients. The side effects, including erythema, stinging, peeling, crusting, and itching, may be sufficient to cause the patient to discontinue the application of the active ingredient before it can  
15 be fully effective. Furthermore, the vehicles of the invention are more cosmetically acceptable and leave no residues of fatty or sticky substances on the skin surface.

While the present invention is believed  
20 to be broadly applicable to a variety of normally irritating active ingredients for topical application to the skin, and particularly to non-water soluble active ingredients, the invention has been found to be particularly useful for the  
25 topical application of retinoids, particularly tretinoin, and the following description will therefore be particularly directed to vehicles and formulations which have been designed for and tested with tretinoin. However, it will be  
30 understood that the broad teachings of this disclosure are applicable to other retinoids, and may be applicable to other normally irritating

active ingredients for topical treatment of the skin.

As used in the present invention, the terms "aqueous" and "aqueous medium" are intended to refer to vehicles and formulations in which the major liquid component is water. Generally speaking, such vehicles and formulations will comprise at least 40% to 50% water and usually more. Thus, the vehicles and formulations of the present invention are to be distinguished from formulations in which the major or primary liquid is an alcohol or other organic solvent.

The gelling agents useful in the present invention are those which form a gel in aqueous medium and hold the retinoid for slow release while allowing the active ingredient to be spread over the skin in a thin, uniform layer while maintaining the integrity of the retinoid molecule. Particularly preferred gelling agents useful in the present invention are the high molecular weight polyacrylate polymers (CAS 9003-01-4) and related polymers which are known agents for use in various types of pharmaceutical and cosmetic compositions. These polyacrylates are formed by neutralizing polyacrylic acids with a base, such as sodium hydroxide or an amine, to an acid pH in the range of about 3 to 7. The neutralization with a base causes the polyacrylic acid to swell (hydrate) to a gel.

Examples of commercially available polyacrylate gelling agents include those sold under the trademark "CARBOPOL", available from the

-9-

B.F. Goodrich Company. The CARBOPOL polymers have high molecular weights ranging from about 250,000 to about 4,000,000. The viscosity of the final gel is dependent on the polymer molecular weight, as well as the concentration of the polymer in the vehicle or formulation. The gelling agent should be present in an amount of about 0.1 to 10 weight percent, depending upon the thickness of the gel desired.

Particularly preferred in the vehicles and formulations of the present invention is CARBOPOL 940 (pharmaceutical grade) which has molecular weights in the range of about 3,000,000 to 4,000,000. This gelling agent is preferably used in an amount of about 0.2 to 0.5 weight percent of the formulation or vehicle. Of course, it will be understood that other CARBOPOL resins such as CARBOPOL 941, CARBOPOL 934P, etc., as well as other polyacrylates and other comparable gelling agents, may be used in the vehicles and formulations of the present invention. In general, the use of different molecular weight polyacrylates will only affect the degree of viscosity obtained.

It has been found according to the invention that the polyacrylate gelling agents have the surprising characteristic of retaining the readily oxidizable retinoid compounds in a protected state, exposed optimally only to the antioxidant. The gelling agent also efficiently spreads the retinoid in a very fine layer over the stratum corneum, which allows percutaneous absorption without excessive spots of retinoid to

-10-

cause skin reaction and irritation, which have been commonly seen with the fatty substrates and gummy substances presently used as vehicles for retinoid application.

- 5           The active ingredients which are applied with the vehicles according to the present invention are preferably retinoids which are commonly used for the treatment of various skin conditions, such as those described above. More  
10 particularly, the active ingredient is the commonly used retinoid tretinoin (Vitamin A acid or all-trans retinoic acid), and its effective, dermatologically acceptable salts, isomers and derivatives thereof, such as isotretinoin (13-cis-  
15 retinoic acid). However, as indicated above, other retinoids and other similarly irritating active ingredients may be used in the vehicles of the present invention to form dermatological compositions for topical treatment of the skin.  
20 The retinoid will generally be present in the formulation in an amount of about 0.01 to 0.1 weight percent of the formulation, and preferably about 0.01 to 0.05 weight percent. However, the amount of retinoid or other irritating active  
25 ingredient may vary depending upon the strength of the retinoid and the particular condition being treated.

- Since the retinoid is more susceptible to oxidation and resulting decomposition when present  
30 in an aqueous medium, the vehicles of the present invention must contain an antioxidant in proportion to the retinoid content. That is, the higher the

-11-

concentration of the retinoid, the more antioxidant which will be required. Generally, the antioxidant should be present in an amount of about 0.01 to 4 weight percent of the formulation. Suitable antioxidants include dl-alpha-tocopherol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbyl palmitate and propyl gallate, for example. Other suitable antioxidants for retinoids will be readily recognized by those skilled in the art.

In addition to the above ingredients, the vehicles and formulations of the present invention may optionally contain other agents and additives which assist in the purposes of the present invention or which are conventionally used in topical dermatological compositions. Since retinoids are generally non-water soluble, it is generally preferred to first dissolve (solubilize) the retinoid in a solvent (solubilizing agent) for the retinoid. In the case of tretinoin, ethanol, isopropanol or another non-ionic alcohol in an amount of about 1 to 20 weight percent of the formulation may be used to first solubilize the retinoid. Thereafter, the alcohol-solubilized retinoid may be combined with an emulsifier in order to form an emulsion in the aqueous medium. The emulsifier is preferably at least one normally liquid glycol, preferably propylene glycol, which may be present in the formulation in an amount of about 1 to 20 percent by weight.

When using a solubilizing agent and/or emulsifier, the formulations of the invention are

-12-

preferably formed by first dissolving the retinoid in the solubilizing agent and combining with the emulsifier and any other organic, lipophilic ingredients. In a separate vessel, the gelling agent is added to water and then neutralized to swell the gel. Thereafter, the solubilized active ingredient and lipophilic agents are added to the swelled gel and mixed to form the final gel emulsion. It will be recognized, however, by those skilled in the art that other methods and means of emulsifying the active ingredient in the aqueous gel may be employed consistent with the teachings of the present invention.

In order to assist the gelling agent in providing the slow release of the retinoid, the formulations of the invention may also include a suitable chelating or sequestering agent, preferably in an amount of up to about 0.5% by weight of the formulation. Suitable chelating agents include, for example, sodium and calcium salts of EDTA, such as disodium EDTA and calcium disodium EDTA.

Further, it may be desirable to include a surfactant as one of the components of the vehicle. Thus, the inclusion of a surfactant may have the dual benefit of helping to maintain the active ingredient in uniform suspension in the formulation, while enhancing the bio-availability of the active ingredient. The surfactant may be present in an amount up to about 20% by weight of the formulation, and may include for example, lecithin; sorbitan monoesters, such as sorbitan

-13-

monoleate, sorbitan monolaurate, sorbitan  
monopalmitate, sorbitan monostearate; polysorbates,  
such as those prepared from lauric, palmitic,  
stearic and oleic acids; polysorbate 20,  
5 mononylphenyl ethers of polyethylene glycols, such  
as the monoxynols; polyoxyethylene monoesters, such  
as polyoxeethylene monostearate, polyoxyethylene  
monolaurate, polyoxyethylene monoleate; dioctyl  
sodium sulfosuccinate; sodium lauryl sulfate; and  
10 polyoximers having a molecular weight between 2,000  
and 8,000; triethanolamine; and ureas such as  
diazolidinyl urea. Preferably, a non-ionic  
surfactant is used if the stability of oxidizable  
ingredients in the formulation is affected by the  
15 ionic strength of the formulation.

Further, the formulations may contain up  
to about 10 weight percent of a lipophilic or  
hydrophobic agent, which may serve as an emollient  
or anti-irritant, as an additional help in  
20 relieving any irritation caused from the retinoid.  
Examples of such lipophilic agents include fatty  
materials such as fatty alcohols of about 12 to 20  
carbon atoms, fatty acid esters having about 12 to  
20 carbon atoms in the fatty acid moiety,  
25 petrolatum, mineral oils, and plant oils such as  
soybean oil, sesame oil, almond oil, aloe vera gel,  
and allantoin.

The formulations and vehicles of the  
present invention may further contain about 0.05 to  
30 2 weight percent of a preservative or anti-  
microbial or anti-bacterial agent which prevents  
bacterial or microbial growth in the gel.

-14-

Preferred preservatives include the parabens, preferably methyl paraben and ethyl paraben, and sorbitol. However, other conventional preservatives commonly used in pharmaceutical compositions will be readily recognized by those skilled in the art.

Finally, the vehicles and formulations of the present invention may optionally contain minor amounts of such other commonly used cosmetic adjuvants or additives as dyes, perfumes, sunscreens, etc., as will be readily recognized by those skilled in the art. In addition, it is also contemplated that the compositions of the invention may contain other topical active medicaments such as vitamins, lipids, hormones or anti-inflammatory agents, such as corticosteroids.

The invention will now be illustrated in more detail with reference to the following specific, non-limiting examples. The following formulation examples were tested for their particular effectiveness in preventing the oxidation of tretinoin. The formulations may contain varying amounts of tretinoin, such as 0.01, 0.025 or 0.05 weight percent. The results of these tests are set forth in Table II below, which shows the percent decomposition of tretinoin in the formulation vehicle after 10 months. Additional decomposition results for formulation Example 2 are set forth after Table II.



-15-

Formulation Example No. 1

	<u>Ingredient</u>	<u>Weight Percent</u>
	CARBOPOL 940	0.4
	Ethanol	3.0
5	Propylene glycol	3.0
	BHT	0.015
	Parabens	0.05
	Tetrasodium EDTA	0.001
	Polyethylene glycol 400	0.05
10	Triethanolamine	0.05
	Water	q.s. to 100

All of the following Formulation Examples 2 through 7 contain the following components in addition to those listed:

15	Parabens	0.05%
	Tetra-sodium EDTA	0.001%
	Polyethylene glycol 400	0.05%
	Triethanolamine	0.05%

Formulation Example No. 2

20	<u>Ingredient</u>	<u>Weight Percent</u>
	CARBOPOL 940	0.50
	Propylene glycol	1.00
	Ethanol	2.00
	BHT	0.015
25	Water	q.s. to 100

Formulation Example No. 3

	<u>Ingredient</u>	<u>Weight Percent</u>
	CARBOPOL 940	1.60
	Propylene glycol	6.00
30	Ethanol	10.00
	BHT	0.03
	Water	q.s. to 100

Formulation Example No. 4

	<u>Ingredient</u>	<u>Weight Percent</u>
	CARBOPOL 940	0.4
	Propylene glycol	20.0
5	Ethanol	20.0
	BHT	0.01
	Water	q.s. to 100

Formulation Example No. 5

	<u>Ingredient</u>	<u>Weight Percent</u>
10	CARBOPOL 940	0.5
	Propylene glycol	10.0
	Ethanol	20.0
	BHT	0.1
	Water	q.s. to 100

Formulation Example No. 6

	<u>Ingredient</u>	<u>Weight Percent</u>
	CARBOPOL 940	0.4
	Propylene glycol	3.5
	Isopropyl alcohol	10.0
20	BHT	0.1
	Water	q.s. to 100

Formulation Example No. 7

	<u>Ingredient</u>	<u>Weight Percent</u>
25	CARBOPOL 940	0.3
	Propylene glycol	1.20
	Isopropyl alcohol	1.90
	BHT	0.01
	Water	q.s. to 100

-17-

Table II  
Stability Test Results

	<u>Formulation Example No.</u>	<u>Percent Decomposition of Tretinoin (10 months)</u>
5	1	11
	2	5
	3	8
	4	11
	5	3
10	7	13

Formulation Example No. 2 was additionally tested for decomposition and found to have 2% decomposition of tretinoin after one month and about 13% decomposition of tretinoin after one  
15 year.

In order to test and demonstrate the effectiveness of the vehicles of the present invention in delivering retinoids in a less irritating manner while retaining therapeutic  
20 efficacy, the following studies were performed.

Animal Studies

In order to assess the bio-equivalency of tretinoin in an aqueous gel base according to the present invention, compared to the presently FDA  
25 approved formulation (RETIN-A), the Rhino mouse model was utilized. Thus, topical tretinoin produces a dose-dependent reduction in the size of the horn-filled utriculi in Rhino mouse epidermis. In this study, equivalent concentrations of  
30 tretinoin (0.025 weight percent) in the CARBOPOL gel formulation of Formulation Example No. 2 and in the RETIN-A cream vehicle were applied daily to the

-18-

dorsal trunk skin of Rhino mice for up to two months. At two-week intervals, biopsies and photographs were taken to assess the effect of the tretinoin on histology, reduction of utriculi and general skin appearance. The resulting histology showed equivalent activity in the Rhino mouse epidermis treated with tretinoin in either the CARBOPOL gel formulation or the RETIN-A formulation.

Similar studies performed with Rhino mice skin at 0.05 percent and higher concentrations of tretinoin showed equivalent activity in both the CARBOPOL gel and RETIN-A formulations.

#### Clinical Studies

Seventy volunteer subjects participated in this study to assess the therapeutic efficacy as well as the irritancy potential of aqueous gel formulations of the present invention versus the RETIN-A cream formulation. These subjects had all previously reported that they could not use the presently available formulations of tretinoin without experiencing irritation sufficient to cause them to discontinue the use of the drug. Subjects were given either a 0.025% or 0.05% tretinoin formulation in the CARBOPOL gel formulation of Formulation Example No. 2 above and were asked to apply the gel twice daily. These subjects were followed for six months, and results were evaluated by the attending dermatologist as well as the patient.

Sixty-seven of the volunteers completed the study. As compared to the 100% irritation

-19-

reported by these volunteers who had all previously used the commercial 0.025% tretinoin formulation of RETIN-A, only 10 reported irritation using the CARBOPOL gel formulation of Example 2 above. Of these, three reported mild irritation with the 0.025% gel formulation, six reported mild irritation with the 0.05% gel formulation, and only one reported moderate irritation with the 0.05% gel formulation. None of the subjects reported severe irritation with either concentration of the gel formulation.

These results demonstrate that the slow release CARBOPOL gel formulations of the present invention were less irritating than the standard RETIN-A cream formulation. Subjects sensitive to RETIN-A were able to tolerate equivalent and stronger concentrations of tretinoin in the gel formulation without as much irritation, and therefore they continued to use the tretinoin as prescribed.

Additional subjects have been tested in studies with 0.01% tretinoin in the gel formulations of the present invention, with similar results being obtained. In general, the slow release gel vehicles of the present invention appear to be an effective method of delivering tretinoin in a less irritating manner while still maintaining therapeutic efficacy.

The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the

appended claims, rather than to the foregoing specification as indicating the scope of the invention.

-21-

CLAIMS

1. A stable, aqueous retinoid composition for topical application to the skin with slow release of the retinoid and minimal irritancy to the skin, comprising:
  - (a) an aqueous medium;
  - (b) an amount of a retinoid effective for treatment of a skin condition;
  - (c) an amount of a gelling agent effective to form a gel and hold said retinoid for slow release in said aqueous medium; and
  - (d) an amount of antioxidant effective to retard decomposition of said retinoid.
2. A composition according to claim 1 comprising about 0.01 to 0.1 weight percent retinoid, about 0.1 to 10 weight percent gelling agent, about 0.01 to 4 weight percent antioxidant, and at least about 50 weight percent water.
3. A composition according to claim 1 wherein said retinoid is selected from the group consisting of tretinoin and effective, dermatologically acceptable salts, isomers and derivatives thereof.
4. A composition according to claim 1 wherein said gelling agent comprises a high molecular weight polyacrylic acid which is neutralized to a pH of about 3 to 7.
5. A composition according to claim 1 wherein said antioxidant is selected from the group consisting of dl-alpha-tocopherol, butylated

-22-

hydroxyanisole, butylated hydroxytoluene, ascorbyl palmitate, and propyl gallate.

6. A composition according to claim 1 which includes about 0.1 to 20 weight percent of a solubilizing agent for said retinoid.

7. A composition according to claim 6 wherein said solubilizing agent is ethanol.

8. A composition according to claim 1 which includes about 0.1 to 20 weight percent of a non-ionic emulsifying agent to form a stable emulsion of said retinoid in water.

9. A composition according to claim 8 wherein said emulsifying agent comprises at least one normally liquid glycol.

10. A composition according to claim 1 which contains a surfactant selected from the group consisting of lecithin, sorbitan monoesters, polysorbates, mononylphenyl ethers of polyethyleneglycols, polyoxyethylene monoesters, dioctyl sodium sulfosuccinate, sodium lauryl sulfate, polyoxamers having a molecular weight of 2000 to 8000, triethanolamine, and ureas.

11. A composition according to claim 1 which includes up to about 10 weight percent of a lipophilic agent.

12. A composition according to claim 11 wherein said lipophilic agent is selected from the group consisting of fatty alcohols of about 12 to 20 carbon atoms, fatty acid esters having about 12 to 20 carbon atoms in the fatty acid moiety, petrolatum, plant oils and mineral oils.



13. A composition according to claim 1 which contains about 0.05 to 2 weight percent of a preservative.

14. A composition according to claim 13 wherein said preservative is selected from the group consisting of methyl paraben, ethyl paraben and sorbitol.

15. A composition according to claim 1 which includes up to about 0.5 weight percent of a chelating agent for said retinoid.

16. A composition according to claim 15 wherein said chelating agent is selected from the group consisting of sodium and calcium salts of EDTA.

17. An aqueous emulsion vehicle for stable, non-irritating, slow-release topical application of a normally irritating, non-water soluble active ingredient to the skin, comprising an aqueous medium, about 0.1 to 10 weight percent of a high molecular weight polyacrylic acid gelling agent which is neutralized to a pH of about 3 to 7, about 1 to 20 weight percent of an agent for solubilizing said active ingredient, about 1 to 20 weight percent of an agent for emulsifying said solubilized active ingredient in said aqueous medium, and about 0.01 to 4 weight percent of an antioxidant to retard decomposition of said active ingredient.

18. A vehicle according to claim 17 wherein said gelling agent comprises about 0.2 to 0.5 weight percent of a polyacrylate having a molecular weight of about 3,000,000 to 4,000,000.

19. A vehicle according to claim 17 wherein said active solubilizing agent is ethanol, said emulsifier is propylene glycol, and the vehicle further contains a surfactant.

5 20. A vehicle according to claim 17 which contains about 0.1 to 10 weight percent of a lipophilic agent.

# INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US90/03219**

<b>I. CLASSIFICATION F SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC <div style="display: flex; justify-content: space-between;"> <span>INT. CL. 5: <b>A61K 31/78</b></span> <span>U.S. CL. <b>424/78, 81</b></span> </div>																				
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border: 1px solid black;">Classification System</th> <th style="border: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">U.S.</td> <td style="border: 1px solid black; vertical-align: top;">424/78, 81 514/859</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	U.S.	424/78, 81 514/859														
Classification System	Classification Symbols																			
U.S.	424/78, 81 514/859																			
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black;">Category <sup>9</sup></th> <th style="border: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%; border: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; vertical-align: top;">US, A, 4,247,547 (MARKS) 27 JANUARY 1981, SEE EXAMPLES.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-20</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; vertical-align: top;">US, A, 4,214,000 (PAPA) 22 JULY 1980, SEE COLUMN 5, AND CLAIMS.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-20</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; vertical-align: top;">US, A, 3,906,108 (FELTY) 16 SEPTEMBER 1975, SEE EXAMPLES.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-20</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; vertical-align: top;">US, A, 3,729,568 (KLINGMAN) 24 APRIL 1973, SEE COLUMNS 2 and 3.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-20</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; vertical-align: top;">GB, A, 906,000 (HOFFMANN-LA ROUCHE) 19 SEPTEMBER 1962, SEE EXAMPLES.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-20</td> </tr> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	US, A, 4,247,547 (MARKS) 27 JANUARY 1981, SEE EXAMPLES.	1-20	Y	US, A, 4,214,000 (PAPA) 22 JULY 1980, SEE COLUMN 5, AND CLAIMS.	1-20	Y	US, A, 3,906,108 (FELTY) 16 SEPTEMBER 1975, SEE EXAMPLES.	1-20	Y	US, A, 3,729,568 (KLINGMAN) 24 APRIL 1973, SEE COLUMNS 2 and 3.	1-20	Y	GB, A, 906,000 (HOFFMANN-LA ROUCHE) 19 SEPTEMBER 1962, SEE EXAMPLES.	1-20
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>																		
Y	US, A, 4,247,547 (MARKS) 27 JANUARY 1981, SEE EXAMPLES.	1-20																		
Y	US, A, 4,214,000 (PAPA) 22 JULY 1980, SEE COLUMN 5, AND CLAIMS.	1-20																		
Y	US, A, 3,906,108 (FELTY) 16 SEPTEMBER 1975, SEE EXAMPLES.	1-20																		
Y	US, A, 3,729,568 (KLINGMAN) 24 APRIL 1973, SEE COLUMNS 2 and 3.	1-20																		
Y	GB, A, 906,000 (HOFFMANN-LA ROUCHE) 19 SEPTEMBER 1962, SEE EXAMPLES.	1-20																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>																				
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; vertical-align: top;">           Date of the Actual Completion of the International Search  <b>02 SEPTEMBER 1990</b> </td> <td style="width: 50%; border: 1px solid black; vertical-align: top;">           Date of Mailing of this International Search Report         </td> </tr> <tr> <td style="border: 1px solid black; vertical-align: top;">           International Searching Authority  <b>ISA/US</b> </td> <td style="border: 1px solid black; vertical-align: top;">           Signature of Authorizing Officer    <b>P. Kulkosky</b> </td> </tr> </table>			Date of the Actual Completion of the International Search <b>02 SEPTEMBER 1990</b>	Date of Mailing of this International Search Report	International Searching Authority <b>ISA/US</b>	Signature of Authorizing Officer  <b>P. Kulkosky</b>														
Date of the Actual Completion of the International Search <b>02 SEPTEMBER 1990</b>	Date of Mailing of this International Search Report																			
International Searching Authority <b>ISA/US</b>	Signature of Authorizing Officer  <b>P. Kulkosky</b>																			